Hikma Pharmaceuticals's market cap is currently £5.06B. The company's EPS TTM is p1.019; its P/E ratio is 22.37; and it has a dividend yield of 2.70%. Hikma Pharmaceuticals is scheduled to report earnings on February 20, 2025, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 2.88B	$ 2.52B	$ 2.55B	$ 2.34B	$ 2.21B
Gross Profit	$ 1.41B	$ 1.26B	$ 1.30B	$ 1.21B	$ 1.10B
Operating Income	$ 367.00M	$ 591.00M	$ 634.00M	$ 540.00M	$ 486.00M
EBITDA	$ 791.00M	$ 485.00M	$ 744.00M	$ 654.00M	$ 584.00M
Net Income	$ 190.00M	$ 188.00M	$ 421.00M	$ 431.00M	$ 486.00M
Balance Sheet
Cash & Short-Term Investments	$ 229.00M	$ 292.00M	$ 450.00M	$ 347.00M	$ 465.00M
Total Assets	$ 4.68B	$ 4.47B	$ 4.37B	$ 4.13B	$ 3.93B
Total Debt	$ 1.19B	$ 1.28B	$ 846.00M	$ 932.00M	$ 685.00M
Net Debt	$ 986.00M	$ 1.01B	$ 420.00M	$ 609.00M	$ 243.00M
Total Liabilities	$ 2.47B	$ 2.32B	$ 1.91B	$ 1.99B	$ 1.80B
Stockholders' Equity	$ 2.20B	$ 2.13B	$ 2.45B	$ 2.13B	$ 2.12B
Cash Flow
Free Cash Flow	$ 439.00M	$ 392.00M	$ 493.00M	$ 292.00M	$ 353.00M
Operating Cash Flow	$ 608.00M	$ 530.00M	$ 638.00M	$ 464.00M	$ 472.00M
Investing Cash Flow	$ -333.00M	$ -607.00M	$ -238.00M	$ -283.00M	$ -151.00M
Financing Cash Flow	$ -337.00M	$ -58.00M	$ -287.00M	$ -298.00M	$ -155.00M

Currency in USD

Hikma Pharmaceuticals Earnings and Revenue History

Income Statement >

Hikma Pharmaceuticals Debt to Assets

Balance Sheet >

Hikma Pharmaceuticals Cash Flow

Cash Flow >

Hikma Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing